	US 11,986,557 B2
	Stealth nanoparticles
Emmanuel Oyekanmi Akala, Mitchellville, MD (US)
Assigned to HOWARD UNIVERSITY, Washington, DC (US)
Filed by HOWARD UNIVERSITY, Washington, DC (US)
Filed on Nov. 27, 2019, as Appl. No. 16/698,297.
Claims priority of provisional application 62/772,489, filed on Nov. 28, 2018.
Prior Publication US 2020/0163884 A1, May 28, 2020
Int. Cl. A61K 9/14 (2006.01); A61K 31/337 (2006.01); A61K 31/395 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/34 (2017.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01)

CPC A61K 9/146 (2013.01) [A61K 31/337 (2013.01); A61K 31/395 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/34 (2013.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01); B82Y 30/00 (2013.01); B82Y 40/00 (2013.01)]

16 Claims

1. A method for preparing a drug loaded nanoparticle comprising:

dissolving a macromonomer, a stabilizer and a crosslinker in a solvent to create a mixture;

adding an initiator system to the mixture;

dissolving a drug in an organic phase containing the mixture;

recovering a candidate drug loaded nanoparticle, and

measuring a zeta potential of the candidate drug loaded nanoparticle, and selecting the candidate drug loaded nanoparticle having the zeta potential of −22.60 mV ±0.46 to −43.49 mV ±1.89 as the drug loaded nanoparticle,

wherein the crosslinker is di (2-methacryloyloxyethoxy)-[2,4-dimethoxyphenyl]methane, and the drug comprises paclitaxel and tanespimycin (17-AAG), and

wherein the initiator system comprises azo-bis-isobutyronitrile, potasium persulfate, 2,2′-azobis-2,4-dimethylvaleronitrile, ammonium persulfate, or 2,2′-azobis [N-(2-carboxyethyl)-2-2-methylpropionamidine].